<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335979">
  <stage>Registered</stage>
  <submitdate>18/09/2010</submitdate>
  <approvaldate>29/09/2010</approvaldate>
  <actrnumber>ACTRN12610000813088</actrnumber>
  <trial_identification>
    <studytitle>Effects of perioperative Recombinant Human Erythropoietin administration on proinflammatory cascade following breast cancer surgery.</studytitle>
    <scientifictitle>A double blinded, randomized, placebo controlled study on the effects of Recombinant Human Erythropoietin on proinflammatory cytokines expression following modified radical mastectomy in females with breast cancer stage II/III</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Female subjects with breast cancer stage II/III undergoing a modified radical mastectomy</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Study group: subcutaneous perioperative administration of Recombinant Human Erythropoietin (10000IU/day, subcutaneously) for 9 preoperative and 2 postoperative days
Also all patients recieved oral iron supplementation (200mg/day) for 9 preoperative and 2 postoperative days</interventions>
    <comparator>Control group:subcutaneous  perioperative administration of placebo subcutaneously for 9 preoperative and 2 postoperative days. Placebo consisted of normal saline 0.9% placed in an identical syringe as the actual drug.
Also all patients recieved oral iron supplementation (200mg/day) for 9 preoperative and 2 postoperative days</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Assesment of cytokines cascade expression with plasma and drainage fluid cytokine assays following the immunomodulation of Recombinant Human Erythropoietin</outcome>
      <timepoint>measured once between 6 am-7am hours on postoperative days 1, 3 and 5</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>not applicable</outcome>
      <timepoint>not applicable</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>The inclusion criterion was defined as an established preoperative diagnosis of breast cancer stage II or III.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(1) hemoglobin concentration&gt;13gr/dl at presentation, (2) previous history of malignancy, (3) history of thromboembolic events, (4) history of seizures, (5) hypertension, (6) known allergy to Recombinant Human Erythropoietin , (7) patients with hepatic, renal, metabolic or endocrine disease, (8) patients receiving medications known to interfere with wound healing, (9) neoadjuvant chemotherapy, (11) recent major surgical procedure or recent history of transfusion  and (12) patients denial to informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed opaque envelopes</concealment>
    <sequence>By means of a computational random number generator</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>28/02/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>22</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Ioannina</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>University Hospital of Ioannina</primarysponsorname>
    <primarysponsoraddress>Panepistimiou Ave, 45500, Ioannina</primarysponsoraddress>
    <primarysponsorcountry>Greece</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>University Hospital of Ioannina</fundingname>
      <fundingaddress>Panepistimiou Ave, 45500, Ioannina</fundingaddress>
      <fundingcountry>Greece</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>It is known that erythropoetin has been used in clinical practice to minimize blood transfusions in the surgical patients. The aim of this study was to evaluate the impact of erythropoetin in the immune system of breast cancer patients stage II/III in the context of the pleotropic properties of the drug that have been recently discovered. Our hypothesis was that by ameliorating the immune response, the drug may have some effect on tumor recurrence.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Committee of the University Hospital of Ioannina</ethicname>
      <ethicaddress>Panepistimiou Ave, 45500 Ioannina</ethicaddress>
      <ethicapprovaldate />
      <hrec>250/10/7/2000</hrec>
      <ethicsubmitdate />
      <ethiccountry>Greece</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Evangelos Lolis</name>
      <address>19, Gorgopotamou St
Marousi 
15123
Athens</address>
      <phone>00306944968481</phone>
      <fax>00302106775153</fax>
      <email>vaglolis@otenet.gr</email>
      <country>Greece</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Evangelos Lolis</name>
      <address>19, Gorgopotamou St
Marousi 
15123
Athens</address>
      <phone>00306944968481</phone>
      <fax>00302106775153</fax>
      <email>vaglolis@otenet.gr</email>
      <country>Greece</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Evangelos Lolis</name>
      <address>19, Gorgopotamou St
Marousi 
15123
Athens</address>
      <phone>00306944968481</phone>
      <fax>00302106775153</fax>
      <email>vaglolis@otenet.gr</email>
      <country>Greece</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>